Back to rankings
China
2

Life sciences and healthcare: foreign firms

Baker McKenzie FenXun logo

Baker McKenzie FenXun

More information
Baker McKenzie FenXun is home to a highly experienced team distinguished by its blend of legal and scientific expertise. This includes qualified medical practitioners as well as lawyers holding PhDs in fields such as molecular biology, biotechnology and pharmacology, assisting medical device, healthcare and life sciences clients on inbound and outbound compliance, IP, and transactional matters. Jointly leading the practice is Isabella Liu, advising global biotechnology businesses on IP issues, while Robert Wright and Derek Poon are noted for their M&A and private equity expertise. Grace Tso specialises in cross-border M&A, corporate restructuring and foreign direct investment into China and Hong Kong. Mini vandePol is well-versed in compliance and investigations.
Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

  • 'The IP team has extensive experience in the pharmaceutical and biotechnology fields and is adept at handling cross-border license-in projects. With high professionalism and smooth communication, they can efficiently resolve key issues such as patents, sublicenses, and compliance. They can provide clear and practical advice in complex transactions.'

  • ‘Senior counsel Yilan Yang and others are not only professionally sound and logically clear, but also have a deep understanding of the actual operations of the pharmaceutical industry. They can quickly address key issues in cross-border license transactions, such as patent ownership, technology transfer compliance, and sub-licensing arrangements, and provide executable solutions.'

Key clients

  • Esisai Co., Ltd.
  • Bain Capital
  • Sino Biopharmaceutical Limited
  • Biozeal LLC (dba "ChildLife")
  • Hasten Biopharmaceutical Co., Ltd.
  • YSB Inc

Work highlights

Advised Eisai Co., Ltd on its license agreement granting the exclusive development and distribution rights for the fibroblast growth factor (FGF) receptor selective tyrosine kinase inhibitor tasurgratinib succinate (TASFYGO) in the Greater China region to a subsidiary of the Singaporean company SciClone Pharmaceuticals (Holdings) Limited.
Assisting Bain Capital as due diligence counsel in connection with its acquisition of Mitsubishi Tanabe Corporation in a carve-out transaction from Mitsubishi Chemical Group Co.
Acted in Hasten Biopharmaceutical Co., Ltd. acquisition of commercial rights to 14 branded products from Korean biopharmaceutical company Celltrion in the Pan-Asia-Pacific region and multiple countries and regions.

Practice head

Isabella Liu; Tracy Wut ; Robert Wright; Derek Poon; Grace Tso; Mini Menon vandePol

Other key lawyers

Yilan Yang